CSBio CSBio

X
[{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Mabylon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"SciNeuro Pharmaceuticals"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Rona Therapeutics"},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Frametact","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cure Genetics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Frametact will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases, such as Alzheimer's, Parkinson's, and Huntington's disease.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Frametact

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems.

            Lead Product(s): RNA Therapeutic

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lilly Asia Ventures

            Deal Size: $33.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA binding protein-43 (TDP-43) and Apolipoprotein E (APOE) for neurodegenerative diseases for which there are currently no effective treatments.

            Lead Product(s): Human Auto-antibodies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mabylon

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY